MTOR and neoplasm: mTOR inhibitors are approved for the treatment of renal cell, neuroendocrine and hormone-positive/HER-2-negative advanced breast cancer.21–23 Recently, the phase II Italian Trials in Medical Oncology (ITMO) trial assessed everolimus activity in patients with chemorefractory advanced BTC, where a favourable toxicity profile and encouraging anti-tumour activity was reported.24